Remdesivir safety and clinical outcomes in pediatric COVID-19: a retrospective study
Leila Barati, Narges lashkarbolouk, Somayeh Ghorbani, Lobat Shahkar · 2025
Read Remdesivir safety and clinical outcomes in pediatric COVID-19: a retrospective study by Leila Barati, Narges lashkarbolouk, Somayeh Ghorbani, Lobat Shahkar (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12750813.txt.
Description
Leila Barati, Narges Lashkarbolouk, Somayeh Ghorbani, and Lobat Shahkar review in 2025 how children with COVID-19 fared on the antiviral drug remdesivir. Their study looked back at records from a hospital in Iran. All the patients were under eighteen, admitted with severe breathing trouble between early 2021 and late 2022, and treated under the national protocol.
Ages ran from twenty-five days to seventeen years, with a median of ten. Fifteen children needed intensive care, and half of those had failure to thrive. Body weight mattered: heavier children over ten showed abnormal chest scans far more often. The drug was well tolerated overall. No child had to stop it, and liver and kidney tests showed no real harm, apart from mild, brief rises in liver enzymes in some. The authors call for forward-looking studies to pin down the drug's role in children.
Catalog record
| CREATOR | Leila Barati, Narges lashkarbolouk, Somayeh Ghorbani, Lobat Shahkar |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |